Cargando…
Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605160/ https://www.ncbi.nlm.nih.gov/pubmed/34608677 http://dx.doi.org/10.1002/jcla.24004 |
_version_ | 1784602116921229312 |
---|---|
author | Lee, Anna Nahm, Chung Hyun Lee, Jin‐Soo Lee, Mi‐Kyeong Lee, Kyoung‐Ryul |
author_facet | Lee, Anna Nahm, Chung Hyun Lee, Jin‐Soo Lee, Mi‐Kyeong Lee, Kyoung‐Ryul |
author_sort | Lee, Anna |
collection | PubMed |
description | BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent assay (ELISA) and multiplex flow immunoassay (MFIA) in hospitalized COVID‐19 patients (N = 105) and healthy controls (N = 38). Anti‐phosphatidylserine/prothrombin antibodies, calprotectin, and C‐reactive protein (CRP) levels were also measured. We assessed the potential correlation between calprotectin levels and various laboratory parameters that were measured during the hospitalization period. After stratifying COVID‐19 patients into two groups by their oxygenation status or acute respiratory distress syndrome presentation, the discriminatory performance of each biomarker was evaluated. RESULTS: A high proportion of COVID‐19 patients (29.5%, 31/105) had low aCL IgM titers that were detectable by ELISA but mostly below the detection limit of MFIA. Calprotectin levels in severe groups of COVID‐19 were significantly higher than those in non‐severe groups, while CRP levels revealed no significant differences. Serum calprotectin levels showed strong to moderate degree of correlation with other routinely used parameters including peak levels of CRP, ferritin, procalcitonin, BUN, and neutrophil‐to‐lymphocyte ratio, but a negative correlation with minimal lymphocyte count and CD4(+) T cells. The discriminatory performance was highest for calprotectin in discriminating severe groups of COVID‐19. CONCLUSIONS: Serum calprotectin levels were significantly elevated in severe COVID‐19 cases. The prevalence of clinically significant aPL did not differ. The link between calprotectin and inflammatory pathway in COVID‐19 may help improve the management and outcomes of COVID‐19 patients. |
format | Online Article Text |
id | pubmed-8605160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86051602021-11-24 Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 Lee, Anna Nahm, Chung Hyun Lee, Jin‐Soo Lee, Mi‐Kyeong Lee, Kyoung‐Ryul J Clin Lab Anal Research Articles BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent assay (ELISA) and multiplex flow immunoassay (MFIA) in hospitalized COVID‐19 patients (N = 105) and healthy controls (N = 38). Anti‐phosphatidylserine/prothrombin antibodies, calprotectin, and C‐reactive protein (CRP) levels were also measured. We assessed the potential correlation between calprotectin levels and various laboratory parameters that were measured during the hospitalization period. After stratifying COVID‐19 patients into two groups by their oxygenation status or acute respiratory distress syndrome presentation, the discriminatory performance of each biomarker was evaluated. RESULTS: A high proportion of COVID‐19 patients (29.5%, 31/105) had low aCL IgM titers that were detectable by ELISA but mostly below the detection limit of MFIA. Calprotectin levels in severe groups of COVID‐19 were significantly higher than those in non‐severe groups, while CRP levels revealed no significant differences. Serum calprotectin levels showed strong to moderate degree of correlation with other routinely used parameters including peak levels of CRP, ferritin, procalcitonin, BUN, and neutrophil‐to‐lymphocyte ratio, but a negative correlation with minimal lymphocyte count and CD4(+) T cells. The discriminatory performance was highest for calprotectin in discriminating severe groups of COVID‐19. CONCLUSIONS: Serum calprotectin levels were significantly elevated in severe COVID‐19 cases. The prevalence of clinically significant aPL did not differ. The link between calprotectin and inflammatory pathway in COVID‐19 may help improve the management and outcomes of COVID‐19 patients. John Wiley and Sons Inc. 2021-10-05 /pmc/articles/PMC8605160/ /pubmed/34608677 http://dx.doi.org/10.1002/jcla.24004 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Lee, Anna Nahm, Chung Hyun Lee, Jin‐Soo Lee, Mi‐Kyeong Lee, Kyoung‐Ryul Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title | Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title_full | Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title_fullStr | Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title_full_unstemmed | Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title_short | Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 |
title_sort | assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe covid‐19 |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605160/ https://www.ncbi.nlm.nih.gov/pubmed/34608677 http://dx.doi.org/10.1002/jcla.24004 |
work_keys_str_mv | AT leeanna assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19 AT nahmchunghyun assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19 AT leejinsoo assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19 AT leemikyeong assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19 AT leekyoungryul assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19 |